Display options
Cite
Micali G, Gerber PA, Lacarrubba F, et al. Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. J Clin Aesthet Dermatol. 2016;9(7):30-9
Micali, G., Gerber, P. A., Lacarrubba, F., & Schäfer, G. (2016). Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. The Journal of clinical and aesthetic dermatology, 9(7), 30-9.
Micali, Giuseppe, et al. "Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features." The Journal of clinical and aesthetic dermatology vol. 9,7 (2016): 30-9.
Micali G, Gerber PA, Lacarrubba F, Schäfer G. Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features. J Clin Aesthet Dermatol. 2016 Jul;9(7):30-9. Epub 2016 Jul 01. PMID: 27672409; PMCID: PMC5023001.
Copy Download .nbib Format: NLM
Share it on

J Clin Aesthet Dermatol. 2016 Jul;9(7):30-9. Epub 2016 Jul 01.

Improving Treatment of Erythematotelangiectatic Rosacea with Laser and/or Topical Therapy Through Enhanced Discrimination of its Clinical Features.

The Journal of clinical and aesthetic dermatology

Giuseppe Micali, Peter Arne Gerber, Francesco Lacarrubba, Gregor Schäfer

Affiliations

  1. Dermatology Clinic, University of Catania, Italy;
  2. Department of Dermatology, Medical Faculty, University of Düsseldorf, Germany;
  3. Galderma International, Paris, France.

PMID: 27672409 PMCID: PMC5023001

Abstract

Rosacea is a chronic inflammatory disease that can present with a variety of cutaneous symptoms. Erythematotelangiectatic rosacea is a subtype characterized by flushing (transient erythema), persistent central facial erythema (background erythema), and telangiectasias. The severity of individual symptoms differs in each patient, which can complicate the selection of an appropriate treatment strategy. Evaluation of these specific symptoms has been greatly improved by the routine use of diagnostic tools such as (video) dermatoscopy. Following a thorough clinical assessment, treatment decisions should be made based on the proportion of these individual symptoms in individual patients. Brimonidine 0.33% gel is recommended in the symptomatic treatment of facial erythema, and there is evidence for the efficacy of laser/light-based therapies in the treatment of erythema and telangiectasias. In patients presenting with both marked background erythema and telangiectasias, initial treatment with brimonidine 0.33% gel to target the erythema followed by laser/light-based therapy for the telangiectasias has been shown to be an effective combination in clinical practice. This article aims to facilitate treatment decision-making in clinical practice through: 1) better differentiation of the main symptoms of erythematotelangiectatic rosacea and 2) practical advice for the selection of appropriate treatments, based on clinical case examples.

References

  1. Br J Dermatol. 2013 Sep;169(3):555-62 - PubMed
  2. Mol Pharmacol. 2009 Oct;76(4):710-22 - PubMed
  3. Dermatol Surg. 2007 Apr;33(4):441-8 - PubMed
  4. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1336-43 - PubMed
  5. Cutis. 2009 Jul;84(1):43-7 - PubMed
  6. J Invest Dermatol. 2014 Nov;134(11):2728-36 - PubMed
  7. J Drugs Dermatol. 2015 Jan;14(1):33-40 - PubMed
  8. J Cosmet Dermatol. 2013 Sep;12(3):187-94 - PubMed
  9. Cutis. 2014 Jul;94(1):21-5 - PubMed
  10. JAMA Dermatol. 2015 Aug;151(8):825-36 - PubMed
  11. J Investig Dermatol Symp Proc. 2011 Dec;15(1):53-62 - PubMed
  12. J Eur Acad Dermatol Venereol. 2014 May;28(5):609-14 - PubMed
  13. J Manag Care Spec Pharm. 2014 Jun;20(6):623-9 - PubMed
  14. J Investig Dermatol Symp Proc. 2011 Dec;15(1):40-7 - PubMed
  15. Lasers Surg Med. 2008 Apr;40(4):233-9 - PubMed
  16. Int J Dermatol. 2014 May;53(5):e325-7 - PubMed
  17. Int J Dermatol. 2003 Jun;42(6):430-3 - PubMed
  18. J Investig Dermatol Symp Proc. 2011 Dec;15(1):24-32 - PubMed
  19. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):474-81 - PubMed
  20. Clin Cosmet Investig Dermatol. 2015 Apr 07;8:159-77 - PubMed
  21. J Drugs Dermatol. 2013 Jun 1;12(6):650-6 - PubMed
  22. J Dermatol Sci. 2009 Aug;55(2):77-81 - PubMed
  23. Ann Dermatol Venereol. 2011 Nov;138 Suppl 3:S179-83 - PubMed
  24. J Investig Dermatol Symp Proc. 2011 Dec;15(1):2-11 - PubMed
  25. Contact Dermatitis. 2008 Mar;58(3):147-55 - PubMed
  26. J Clin Aesthet Dermatol. 2012 Mar;5(3):16-25 - PubMed
  27. J Am Acad Dermatol. 2013 Dec;69(6 Suppl 1):S44-56 - PubMed
  28. Int J Dermatol. 1998 Apr;37(4):263-6 - PubMed
  29. J Cutan Pathol. 2007 Oct;34(10):748-53 - PubMed
  30. J Drugs Dermatol. 2014 Jan;13(1):56-61 - PubMed
  31. Dermatol Surg. 2003 Jan;29(1):56-8 - PubMed
  32. J Am Acad Dermatol. 2011 Jun;64(6):1135-46 - PubMed
  33. J Am Acad Dermatol. 2002 Apr;46(4):584-7 - PubMed
  34. Cochrane Database Syst Rev. 2015 Apr 28;(4):CD003262 - PubMed
  35. J Dermatol Sci. 2014 Jul;75(1):49-54 - PubMed
  36. J Am Acad Dermatol. 2013 Sep;69(3):438-43 - PubMed
  37. Br J Dermatol. 2008 Sep;159(3):628-32 - PubMed
  38. Skin Res Technol. 2007 Nov;13(4):472-84 - PubMed
  39. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):188-200 - PubMed
  40. Lasers Med Sci. 2002;17(1):26-33 - PubMed
  41. J Am Acad Dermatol. 2015 May;72(5):749-58; quiz 759-60 - PubMed
  42. J Investig Dermatol Symp Proc. 2011 Dec;15(1):16-23 - PubMed
  43. J Am Acad Dermatol. 2006 Jan;54(1):100-4 - PubMed
  44. Lasers Med Sci. 2010 Jan;25(1):151-4 - PubMed
  45. Br J Dermatol. 2012 Mar;166(3):633-41 - PubMed
  46. Arch Dermatol Res. 2008 Mar;300(3):125-31 - PubMed
  47. J Drugs Dermatol. 2014 Jun;13(6):699-704 - PubMed
  48. J Clin Aesthet Dermatol. 2015 Sep;8(9):33-8 - PubMed
  49. J Am Acad Dermatol. 2007 Nov;57(5):800-5 - PubMed

Publication Types